Search PubMed⌕ Search

Biomedical subjects

M Prat

Publications and source records attributed to M Prat.

103 records · Page 6Linked to original sources
PubMedDate not supplied

Interferon-gamma plays a crucial role in T lymphocyte reaction against alloantigens.

In this study we report that addition to mixed lymphocyte reactions of monoclonal antibodies to interferon-gamma inhibits alloantigen recognition and induction of cytotoxic T lymphocytes by inducing early and highly effective suppressor T lymphocytes. This inhibitory activity is not confined to in vitro models, since daily local injection of these antibodies in CBA/J mice blocks the rejection of fully allogeneic tumor cells consistently displayed by untreated CBA/J mice.

Animals↗
PubMedDate not supplied

The monoclonal antibody-defined CAR-3 antigen is a serological marker associated with pancreatic carcinoma.

The monoclonal antibody-defined CAR-3 antigen is a new carcinoma associated marker which is expressed on a mucin-like molecule. Serum concentrations of CAR-3 were assayed in 181 patients with carcinomas of different organs, 20 patients with non-carcinomatous malignancies, 123 patients with inflammatory diseases and 150 healthy controls. Serum levels of CAR-3 were significantly increased in 51% of the patients with pancreatic carcinomas, in 60% of patients with biliary tract carcinomas and in about 15% of the patients with carcinomas of the digestive apparatus. Sera from patients with breast carcinomas were negative, as well as sera from patients with melanomas or sarcomas. CAR-3 values in samples from patients with chronic pancreatitis were constantly negative, as were samples from healthy donors. Significant concentrations of CAR-3 were detected in 20% of the sera from patients with acute pancreatitis and in 15% of the sera from patients with cirrhosis. Because of its high specificity for pancreatic carcinomas compared to chronic pancreatitis, CAR-3 seems a promising marker for distinguishing between neoplastic and chronic inflammatory diseases of the pancreas, whose differential diagnosis is difficult.

Adult↗
PubMedDate not supplied

Monoclonal antibodies against laryngeal carcinomas. Preliminary report.

Following types of monoclonal antibodies (MoAb) (HMFG 1, 2 and AI 16.9) were used in twenty patients with laryngeal carcinomas (10 pharyngolaryngeal carcinomas, T4 N+ MO, and 10 vestibulo-glottic carcinomas, T1 T2, N+ N-, MO). The demonstration of MoAb's binding was performed with immunoperoxidase technique. The results demonstrate that the HMFG 1 and 2 antibodies fixed to both T and N, mostly good or very good, while the AI 16.9 antibody fixed in a various way. None of these three MoAb's was specific for the tissue of metastasis-free satellite lymph nodes.

Antibodies, Monoclonal↗